Evommune (EVMN) Gains from Investment Securities (2024 - 2026)

Evommune (EVMN) has 3 years of Gains from Investment Securities data on file, last reported at $100000.0 in Q1 2026.

• Gains from Investment Securities for Q1 2026 came in at $100000.0, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was $401000.0 (changed N/A YoY), and the FY2025 annual result was $6.6 million, up 1382.88% from the prior year.
• Gains from Investment Securities declined to $100000.0 in Q1 2026 per EVMN's latest filing, from $395000.0 in the prior quarter.
• Over five years, Gains from Investment Securities peaked at $395000.0 in Q4 2025 and troughed at -$94000.0 in Q4 2024.
• A 3-year average of $103930.8 and a median of $57361.5 in 2025 frame the typical range for Gains from Investment Securities.
• On a YoY basis, Gains from Investment Securities climbed as much as 520.21% in 2025 and fell as far as 520.21% in 2025.
• A 3-year view of Gains from Investment Securities shows it stood at -$94000.0 in 2024, then jumped by 520.21% to $395000.0 in 2025, then plunged by 74.68% to $100000.0 in 2026.
• Business Quant data shows EVMN's Gains from Investment Securities at $100000.0 in Q1 2026, $395000.0 in Q4 2025, and $14723.0 in Q3 2025.